Cargando…

Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS

Few reports suggested a prognostic impact of Wilms‘Tumor-1 (WT1)-mRNA overexpression in MDS, but translation into clinical routine was hampered by limited patients numbers, differing sample sources, non-standardized methods/cut-offs. To evaluate whether WT1-mRNA expression yields additional prognost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rautenberg, Christina, Germing, Ulrich, Pechtel, Sabrina, Lamers, Marius, Fischermanns, Carolin, Jäger, Paul, Geyh, Stefanie, Haas, Rainer, Kobbe, Guido, Schroeder, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851368/ https://www.ncbi.nlm.nih.gov/pubmed/31719523 http://dx.doi.org/10.1038/s41408-019-0248-y

Ejemplares similares

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
por: Rautenberg, Christina, et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience
por: Jäger, Paul, et al.
Publicado: (2023)

Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
por: Rautenberg, Christina, et al.
Publicado: (2019)

Mesenchymal stromal cells in myeloid malignancies
por: Schroeder, Thomas, et al.
Publicado: (2016)

Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia
por: Geyh, Stefanie, et al.
Publicado: (2018)

Impaired formation of neutrophil extracellular traps in patients with MDS
por: Brings, Carolin, et al.
Publicado: (2022)

Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component
por: Platte, Victoria, et al.
Publicado: (2022)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients
por: Strapatsas, Judith, et al.
Publicado: (2021)

Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial
por: Schroeder, Thomas, et al.
Publicado: (2023)

Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
por: Kasprzak, Annika, et al.
Publicado: (2021)

Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes
por: Kasprzak, A., et al.
Publicado: (2020)

P790: THE EXPRESSION LEVEL OF WT1 MRNA IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE (ICUS) PROGRESSING TO MYELODYSPLASTIC SYNDROME (MDS)
por: Ye, X., et al.
Publicado: (2022)

Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies
por: Germing, Ulrich, et al.
Publicado: (2019)

A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): A case report
por: Schroeder, Thomas, et al.
Publicado: (2008)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS
por: Hofman, Isabel Juliana F., et al.
Publicado: (2022)

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance
por: de Swart, Louise, et al.
Publicado: (2017)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice
por: Annesley, Colleen E., et al.
Publicado: (2018)

P725: BATTLE OF THE GIANTS – COMPARISON OF IPSS-M AND IPSS-R IN PATIENTS WITH MISSING MOLECULAR DATA EXCEPT TP53 MUTATION STATUS FROM THE DÜSSELDORF MDS REGISTRY
por: Schulz, Felicitas, et al.
Publicado: (2023)

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
por: Germing, Ulrich, et al.
Publicado: (2023)

Prognostic impact of peripheral blood Wilms’ tumour 1 mRNA expression levels in response to azacytidine in MDS: A single-centre analysis
por: Maeda, Tomoya, et al.
Publicado: (2020)

Therapy-related myeloid neoplasms following treatment for multiple myeloma—a single center analysis
por: Boquoi, A., et al.
Publicado: (2022)

ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)

Software needs for MDs
por: Ruggiero, F
Publicado: (1993)

LHC MDS For 2018
por: Tomás, R, et al.
Publicado: (2019)

Bogus "M.Ds."
por: Karnik, C. H.
Publicado: (1929)

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
por: Benteyn, Daphné, et al.
Publicado: (2013)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations
por: Boquoi, Amelie, et al.
Publicado: (2022)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
por: Machowicz, Rafal, et al.
Publicado: (2023)

PS Beams for SPS MDs
por: Manglunki, Django
Publicado: (1998)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

William Jarvie, M.D.S.
Publicado: (1922)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
por: Letsch, Anne, et al.
Publicado: (2013)

EASIX for prediction of survival in lower-risk myelodysplastic syndromes
por: Merz, Almuth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_09o3ri5s24nk5r45kid2lrko28